TP53 and prostate carcinoma: Recently, the frequency of driver mutations including TP53, WNT, and cell cycle genes in metastatic hormone-naive prostate cancer has been shown to correlate directly with increased metastatic burden, consistent with the spectral theory of metastasis, including the concept of oligometastatic prostate cancer [9].